TY - JOUR
T1 - Quantifying Atherogenic Lipoproteins
T2 - Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
AU - EAS
AU - European Federation Clinical Ch
AU - Langlois, Michel R.
AU - Chapman, M. John
AU - Cobbaert, Christa
AU - Mora, Samia
AU - Remaley, Alan T.
AU - Ros, Emilio
AU - Watts, Gerald F.
AU - Boren, Jan
AU - Baum, Hannsjoerg
AU - Bruckert, Eric
AU - Catapano, Alberico
AU - Descamps, Olivier S.
AU - von Eckardstein, Arnold
AU - Kamstrup, Pia R.
AU - Kolovou, Genovefa
AU - Kronenberg, Florian
AU - Langsted, Anne
AU - Pulkki, Kari
AU - Rifai, Nader
AU - Sypniewska, Grazyna
AU - Wiklund, Olov
AU - Nordestgaard, Borge G.
PY - 2018/7
Y1 - 2018/7
N2 - BACKGROUND: The European Atherosclerosis Society- European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management.CONTENT: We critically examined LDL cholesterol, non-HDL cholesterol, apolipoprotein B (apoB), and LDL particle number assays based on key criteria for medical application of biomarkers. (a) Analytical performance: Discordant LDL cholesterol quantification occurs when LDL cholesterol is measured or calculated with different assays, especially in patients with hypertriglyceridemia >175 mg/dL (2 mmol/L) and low LDL cholesterol concentrationsSUMMARY: Follow-up of pre- and on-treatment (measured or calculated) LDL cholesterol concentration in a patient should ideally be performed with the same documented test method. Non-HDL cholesterol (or apoB) should be the secondary treatment target in patients with mild to moderate hypertriglyceridemia, in whom LDL cholesterol measurement or calculation is less accurate and often less predictive of cardiovascular risk. Laboratories should report non-HDL cholesterol in all standard lipid panels. (C) 2018 American Association for Clinical Chemistry
AB - BACKGROUND: The European Atherosclerosis Society- European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management.CONTENT: We critically examined LDL cholesterol, non-HDL cholesterol, apolipoprotein B (apoB), and LDL particle number assays based on key criteria for medical application of biomarkers. (a) Analytical performance: Discordant LDL cholesterol quantification occurs when LDL cholesterol is measured or calculated with different assays, especially in patients with hypertriglyceridemia >175 mg/dL (2 mmol/L) and low LDL cholesterol concentrationsSUMMARY: Follow-up of pre- and on-treatment (measured or calculated) LDL cholesterol concentration in a patient should ideally be performed with the same documented test method. Non-HDL cholesterol (or apoB) should be the secondary treatment target in patients with mild to moderate hypertriglyceridemia, in whom LDL cholesterol measurement or calculation is less accurate and often less predictive of cardiovascular risk. Laboratories should report non-HDL cholesterol in all standard lipid panels. (C) 2018 American Association for Clinical Chemistry
KW - LOW-DENSITY-LIPOPROTEIN
KW - NON-HDL-CHOLESTEROL
KW - EUROPEAN ATHEROSCLEROSIS SOCIETY
KW - NUCLEAR-MAGNETIC-RESONANCE
KW - LIPID-LOWERING THERAPY
KW - CORONARY-HEART-DISEASE
KW - HIGH-INTENSITY STATIN
KW - INSULIN-RESISTANCE ATHEROSCLEROSIS
KW - TRIGLYCERIDE-RICH LIPOPROTEINS
KW - CARDIOVASCULAR RISK REDUCTION
U2 - 10.1373/clinchem.2018.287037
DO - 10.1373/clinchem.2018.287037
M3 - Article
VL - 64
SP - 1006
EP - 1033
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 7
ER -